HDL in infectious diseases and sepsis

© The Author(s) 2015. During infection significant alterations in lipid metabolism and lipoprotein composition occur. Triglyceride and VLDL cholesterol levels increase, while reduced HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels are observed. More importantly, endotoxemia modulates HDL...

Full description

Bibliographic Details
Main Authors: Pirillo, A., Catapano, A., Norata, Giuseppe
Format: Conference Paper
Published: 2015
Online Access:http://hdl.handle.net/20.500.11937/55147
_version_ 1848759546891206656
author Pirillo, A.
Catapano, A.
Norata, Giuseppe
author_facet Pirillo, A.
Catapano, A.
Norata, Giuseppe
author_sort Pirillo, A.
building Curtin Institutional Repository
collection Online Access
description © The Author(s) 2015. During infection significant alterations in lipid metabolism and lipoprotein composition occur. Triglyceride and VLDL cholesterol levels increase, while reduced HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels are observed. More importantly, endotoxemia modulates HDL composition and size: phospholipids are reduced as well as apolipoprotein (apo) A-I, whileserum amyloid A (SAA) and secretory phospholipase A2 (sPLA2) dramatically increase, and, although the total HDL particle number does not change, a significant decrease in the number of small- and medium-size particles is observed. Low HDL-C levels inversely correlate with the severity of septic disease and associate with an exaggerated systemic inflammatory response. HDL, as well as other plasma lipoproteins, can bind and neutralize Gramnegative bacterial lipopolysaccharide (LPS) and Gram-positive bacterial lipoteichoic acid (LTA), thus favoring the clearance of these products. HDLs are emerging also as a relevant player during parasitic infections, and a specific component of HDL, namely, apoL-1, confers innate immunity against trypanosome by favoring lysosomal swelling which kills the parasite. During virus infections, proteins associated with the modulation of cholesterol bioavailability in the lipid rafts such as ABCA1 and SR-BI have been shown to favor virus entry into the cells. Pharmacological studies support the benefit of recombinant HDL or apoA-I mimetics during bacterial infection, while apoL-1-nanobody complexes were tested for trypanosome infection. Finally, SR-BI antagonism represents a novel and forefront approach interfering with hepatitis C virus entry which is currently tested in clinical studies. From the coming years, we have to expect new and compelling observations further linking HDL to innate immunity and infections.
first_indexed 2025-11-14T10:01:37Z
format Conference Paper
id curtin-20.500.11937-55147
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:01:37Z
publishDate 2015
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-551472018-03-29T09:09:25Z HDL in infectious diseases and sepsis Pirillo, A. Catapano, A. Norata, Giuseppe © The Author(s) 2015. During infection significant alterations in lipid metabolism and lipoprotein composition occur. Triglyceride and VLDL cholesterol levels increase, while reduced HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels are observed. More importantly, endotoxemia modulates HDL composition and size: phospholipids are reduced as well as apolipoprotein (apo) A-I, whileserum amyloid A (SAA) and secretory phospholipase A2 (sPLA2) dramatically increase, and, although the total HDL particle number does not change, a significant decrease in the number of small- and medium-size particles is observed. Low HDL-C levels inversely correlate with the severity of septic disease and associate with an exaggerated systemic inflammatory response. HDL, as well as other plasma lipoproteins, can bind and neutralize Gramnegative bacterial lipopolysaccharide (LPS) and Gram-positive bacterial lipoteichoic acid (LTA), thus favoring the clearance of these products. HDLs are emerging also as a relevant player during parasitic infections, and a specific component of HDL, namely, apoL-1, confers innate immunity against trypanosome by favoring lysosomal swelling which kills the parasite. During virus infections, proteins associated with the modulation of cholesterol bioavailability in the lipid rafts such as ABCA1 and SR-BI have been shown to favor virus entry into the cells. Pharmacological studies support the benefit of recombinant HDL or apoA-I mimetics during bacterial infection, while apoL-1-nanobody complexes were tested for trypanosome infection. Finally, SR-BI antagonism represents a novel and forefront approach interfering with hepatitis C virus entry which is currently tested in clinical studies. From the coming years, we have to expect new and compelling observations further linking HDL to innate immunity and infections. 2015 Conference Paper http://hdl.handle.net/20.500.11937/55147 10.1007/978-3-319-09665-0_15 restricted
spellingShingle Pirillo, A.
Catapano, A.
Norata, Giuseppe
HDL in infectious diseases and sepsis
title HDL in infectious diseases and sepsis
title_full HDL in infectious diseases and sepsis
title_fullStr HDL in infectious diseases and sepsis
title_full_unstemmed HDL in infectious diseases and sepsis
title_short HDL in infectious diseases and sepsis
title_sort hdl in infectious diseases and sepsis
url http://hdl.handle.net/20.500.11937/55147